Novo Nordisk Faces Setback with Monlunabant Trial Results ...Middle East

On Friday, shares of Novo Nordisk plummeted by over 4%, reaching their lowest point since August 10, following the release of unsatisfactory Phase 2a trial results for its experimental obesity medication, Monlunabant.

Hence then, the article about novo nordisk faces setback with monlunabant trial results was published today ( Friday 20/09/2024 - 05:20 PM ) and is available on Devdiscourse ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Novo Nordisk Faces Setback with Monlunabant Trial Results )

Also on site :

• Top NY judge hands yet another gift to violent criminals at the expense of law-abiding citizens
• US must halt the terror-driven gold rush that’s looting Venezuela
• Best of the Babylon Bee: US votes to legally adopt World Cup fan Freddy the German